Cargando…

COVID-19 pandemic and other factors associated with unfavorable tuberculosis treatment outcomes—Almaty, Kazakhstan, 2018–2021

INTRODUCTION: The COVID-19 pandemic negatively influenced the availability of tuberculosis (TB) services, such as detection, diagnosis and treatment, around the world, including Kazakhstan. We set out to estimate the COVID-19 pandemic influence on TB treatment outcomes by comparing outcomes among pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabdullina, Malika, Maes, Edmond F., Horth, Roberta Z., Dzhazybekova, Panagul, Amanova, Gulzhan N., Zikriyarova, Sanam, Nabirova, Dilyara A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552263/
https://www.ncbi.nlm.nih.gov/pubmed/37808989
http://dx.doi.org/10.3389/fpubh.2023.1247661
_version_ 1785115923915472896
author Gabdullina, Malika
Maes, Edmond F.
Horth, Roberta Z.
Dzhazybekova, Panagul
Amanova, Gulzhan N.
Zikriyarova, Sanam
Nabirova, Dilyara A.
author_facet Gabdullina, Malika
Maes, Edmond F.
Horth, Roberta Z.
Dzhazybekova, Panagul
Amanova, Gulzhan N.
Zikriyarova, Sanam
Nabirova, Dilyara A.
author_sort Gabdullina, Malika
collection PubMed
description INTRODUCTION: The COVID-19 pandemic negatively influenced the availability of tuberculosis (TB) services, such as detection, diagnosis and treatment, around the world, including Kazakhstan. We set out to estimate the COVID-19 pandemic influence on TB treatment outcomes by comparing outcomes among people starting treatment before the pandemic (2018–2019) and during the pandemic (2020–2021) and to determine risk factors associated with unfavorable outcomes. METHODS: We conducted a retrospective cohort study among all people newly diagnosed with drug-sensitive pulmonary or extrapulmonary TB at least 18 years old who initiated treatment from 2018 to 2021 in Almaty. We abstracted data from the national electronic TB register. Unfavorable treatment outcomes were ineffective treatment, death, loss to follow-up, results not evaluated, and transferred. We used multivariable Poisson regression to calculate adjusted relative risk (aRR) and 95% confidence intervals (95%CI). RESULTS: Among 1548 people newly diagnosed with TB during the study period, average age was 43 years (range 18–93) and 52% were male. The number of people initiating treatment was higher before than the pandemic (935 vs. 613, respectively). There was significantly different proportions before compared to during the pandemic for people diagnosed through routine screening (39% vs. 31%, p < 0.001), 60 years and older (16% vs. 22%, p = 0.005), and with diabetes (5% vs. 8%, p = 0.017). There was no difference in the proportion of HIV (8% in both periods). Unfavorable outcomes increased from 11 to 20% during the pandemic (aRR = 1.83; 95% CI: 1.44–2.31). Case fatality rose from 6 to 9% (p = 0.038). Risk factors for unfavorable TB treatment outcomes among all participants were being male (aRR = 1.44, 95%CI = 1.12–1.85), having HIV (aRR = 2.72, 95%CI = 1.99–3.72), having alcohol use disorder (aRR = 2.58, 95%CI = 1.83–3.62) and experiencing homelessness (aRR = 2.94, 95%CI = 1.80–4.80). Protective factors were being 18–39 years old (aRR = 0.33, 95%CI = 0.24–0.44) and 40–59 years old (aRR = 0.56, 95%CI = 0.41–0.75) compared to 60 years old and up. CONCLUSION: COVID-19 pandemic was associated with unfavorable treatment outcomes for people newly diagnosed with drug-sensitive TB in Almaty, Kazakhstan. People with fewer comorbidities were at increased risk. Results point to the need to maintain continuity of care for persons on TB treatment, especially those at higher risk for poor outcomes during periods of healthcare service disruption.
format Online
Article
Text
id pubmed-10552263
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105522632023-10-06 COVID-19 pandemic and other factors associated with unfavorable tuberculosis treatment outcomes—Almaty, Kazakhstan, 2018–2021 Gabdullina, Malika Maes, Edmond F. Horth, Roberta Z. Dzhazybekova, Panagul Amanova, Gulzhan N. Zikriyarova, Sanam Nabirova, Dilyara A. Front Public Health Public Health INTRODUCTION: The COVID-19 pandemic negatively influenced the availability of tuberculosis (TB) services, such as detection, diagnosis and treatment, around the world, including Kazakhstan. We set out to estimate the COVID-19 pandemic influence on TB treatment outcomes by comparing outcomes among people starting treatment before the pandemic (2018–2019) and during the pandemic (2020–2021) and to determine risk factors associated with unfavorable outcomes. METHODS: We conducted a retrospective cohort study among all people newly diagnosed with drug-sensitive pulmonary or extrapulmonary TB at least 18 years old who initiated treatment from 2018 to 2021 in Almaty. We abstracted data from the national electronic TB register. Unfavorable treatment outcomes were ineffective treatment, death, loss to follow-up, results not evaluated, and transferred. We used multivariable Poisson regression to calculate adjusted relative risk (aRR) and 95% confidence intervals (95%CI). RESULTS: Among 1548 people newly diagnosed with TB during the study period, average age was 43 years (range 18–93) and 52% were male. The number of people initiating treatment was higher before than the pandemic (935 vs. 613, respectively). There was significantly different proportions before compared to during the pandemic for people diagnosed through routine screening (39% vs. 31%, p < 0.001), 60 years and older (16% vs. 22%, p = 0.005), and with diabetes (5% vs. 8%, p = 0.017). There was no difference in the proportion of HIV (8% in both periods). Unfavorable outcomes increased from 11 to 20% during the pandemic (aRR = 1.83; 95% CI: 1.44–2.31). Case fatality rose from 6 to 9% (p = 0.038). Risk factors for unfavorable TB treatment outcomes among all participants were being male (aRR = 1.44, 95%CI = 1.12–1.85), having HIV (aRR = 2.72, 95%CI = 1.99–3.72), having alcohol use disorder (aRR = 2.58, 95%CI = 1.83–3.62) and experiencing homelessness (aRR = 2.94, 95%CI = 1.80–4.80). Protective factors were being 18–39 years old (aRR = 0.33, 95%CI = 0.24–0.44) and 40–59 years old (aRR = 0.56, 95%CI = 0.41–0.75) compared to 60 years old and up. CONCLUSION: COVID-19 pandemic was associated with unfavorable treatment outcomes for people newly diagnosed with drug-sensitive TB in Almaty, Kazakhstan. People with fewer comorbidities were at increased risk. Results point to the need to maintain continuity of care for persons on TB treatment, especially those at higher risk for poor outcomes during periods of healthcare service disruption. Frontiers Media S.A. 2023-09-21 /pmc/articles/PMC10552263/ /pubmed/37808989 http://dx.doi.org/10.3389/fpubh.2023.1247661 Text en Copyright © 2023 Gabdullina, Maes, Horth, Dzhazybekova, Amanova, Zikriyarova and Nabirova. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Gabdullina, Malika
Maes, Edmond F.
Horth, Roberta Z.
Dzhazybekova, Panagul
Amanova, Gulzhan N.
Zikriyarova, Sanam
Nabirova, Dilyara A.
COVID-19 pandemic and other factors associated with unfavorable tuberculosis treatment outcomes—Almaty, Kazakhstan, 2018–2021
title COVID-19 pandemic and other factors associated with unfavorable tuberculosis treatment outcomes—Almaty, Kazakhstan, 2018–2021
title_full COVID-19 pandemic and other factors associated with unfavorable tuberculosis treatment outcomes—Almaty, Kazakhstan, 2018–2021
title_fullStr COVID-19 pandemic and other factors associated with unfavorable tuberculosis treatment outcomes—Almaty, Kazakhstan, 2018–2021
title_full_unstemmed COVID-19 pandemic and other factors associated with unfavorable tuberculosis treatment outcomes—Almaty, Kazakhstan, 2018–2021
title_short COVID-19 pandemic and other factors associated with unfavorable tuberculosis treatment outcomes—Almaty, Kazakhstan, 2018–2021
title_sort covid-19 pandemic and other factors associated with unfavorable tuberculosis treatment outcomes—almaty, kazakhstan, 2018–2021
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552263/
https://www.ncbi.nlm.nih.gov/pubmed/37808989
http://dx.doi.org/10.3389/fpubh.2023.1247661
work_keys_str_mv AT gabdullinamalika covid19pandemicandotherfactorsassociatedwithunfavorabletuberculosistreatmentoutcomesalmatykazakhstan20182021
AT maesedmondf covid19pandemicandotherfactorsassociatedwithunfavorabletuberculosistreatmentoutcomesalmatykazakhstan20182021
AT horthrobertaz covid19pandemicandotherfactorsassociatedwithunfavorabletuberculosistreatmentoutcomesalmatykazakhstan20182021
AT dzhazybekovapanagul covid19pandemicandotherfactorsassociatedwithunfavorabletuberculosistreatmentoutcomesalmatykazakhstan20182021
AT amanovagulzhann covid19pandemicandotherfactorsassociatedwithunfavorabletuberculosistreatmentoutcomesalmatykazakhstan20182021
AT zikriyarovasanam covid19pandemicandotherfactorsassociatedwithunfavorabletuberculosistreatmentoutcomesalmatykazakhstan20182021
AT nabirovadilyaraa covid19pandemicandotherfactorsassociatedwithunfavorabletuberculosistreatmentoutcomesalmatykazakhstan20182021